Osmetti L, Allen K, Kozlowski D
Int J Transgend Health. 2025; 26(1):25-49.
PMID: 39981286
PMC: 11837921.
DOI: 10.1080/26895269.2024.2367653.
Ravnborg N, Aslam M, Norup P, Tingsgard J, Pagsberg A, Haahr M
J Clin Med. 2024; 13(22).
PMID: 39597802
PMC: 11595080.
DOI: 10.3390/jcm13226658.
Rahman S, Manasrah N, Kumar N, Hamza M, Sharma A, Patel N
JACC Adv. 2024; 3(10):101265.
PMID: 39309657
PMC: 11414688.
DOI: 10.1016/j.jacadv.2024.101265.
Jessani A, Berry-Moreau T, Parmar R, Athanasakos A, Prodger J, Mujugira A
BMC Glob Public Health. 2024; 2(1):44.
PMID: 38948028
PMC: 11208260.
DOI: 10.1186/s44263-024-00073-2.
Santi D, Spaggiari G, Marinelli L, Cacciani M, Scipio S, Bichiri A
J Endocrinol Invest. 2023; 47(5):1091-1100.
PMID: 37889433
DOI: 10.1007/s40618-023-02220-2.
Cardiovascular Risk Factors in Transgender People after Gender-Affirming Hormone Therapy.
Sanchez-Toscano E, Dominguez-Riscart J, Larran-Escandon L, Mateo-Gavira I, Aguilar-Diosdado M
J Clin Med. 2023; 12(19).
PMID: 37834785
PMC: 10573211.
DOI: 10.3390/jcm12196141.
Thromboembolic risk with gender-affirming hormone therapy: potential role of global coagulation and fibrinolysis assays.
Bouck E, Grinsztejn E, McNamara M, Stavrou E, Wolberg A
Res Pract Thromb Haemost. 2023; 7(6):102197.
PMID: 37822706
PMC: 10562871.
DOI: 10.1016/j.rpth.2023.102197.
Implications of gender-affirming endocrine care for sports participation.
Moreland E, Cheung A, Hiam D, Nolan B, Landen S, Jacques M
Ther Adv Endocrinol Metab. 2023; 14:20420188231178373.
PMID: 37323162
PMC: 10262668.
DOI: 10.1177/20420188231178373.
Correction of Areolar Protuberance During Augmentation Mammoplasty in Transfemale Patients.
Yasar E, Demir C, Asadov M, Alagoz M
J Cutan Aesthet Surg. 2023; 15(4):412-415.
PMID: 37035598
PMC: 10081475.
DOI: 10.4103/JCAS.JCAS_51_21.
Cardiovascular disease and feminizing gender-affirming hormone therapy: Implications for the provision of safe and lifesaving care.
Pribish A, Iwamoto S
Curr Opin Physiol. 2023; 33.
PMID: 36968433
PMC: 10035588.
DOI: 10.1016/j.cophys.2023.100650.
Hormone Prescription and HIV Screening/Preventive Practices Among Clinicians Providing Care for Transgender Individuals.
Toribio M, Cetlin M, Fulda E, Chu S, Gomez Tejeda Zanudo J, Poteat T
Transgend Health. 2023; 8(1):64-73.
PMID: 36824383
PMC: 9942173.
DOI: 10.1089/trgh.2021.0118.
Endocrinological Follow-Up Characteristics of People Diagnosed with Gender Dysphoria in Turkey.
Durcan E, Sulu C, Sahin S, Gioventikli A, Dedeoglu S, Azamet I
Transgend Health. 2023; 7(3):250-260.
PMID: 36643062
PMC: 9829137.
DOI: 10.1089/trgh.2021.0045.
Health Insurance Prevalence Among Gender Minority People: A Systematic Review and Meta-Analysis.
Clark K, Sherman A, Flentje A
Transgend Health. 2022; 7(4):292-302.
PMID: 36033215
PMC: 9398476.
DOI: 10.1089/trgh.2020.0182.
Use of Hormones Among Trans Women in the West Coast of Peninsular Malaysia: A Mixed Methods Study.
Rashid A, Afiqah S, Iguchi Y
Transgend Health. 2022; 7(3):242-249.
PMID: 35785047
PMC: 9245722.
DOI: 10.1089/trgh.2020.0119.
Uncovering the effects of gender affirming hormone therapy on skeletal muscle and epigenetics: protocol for a prospective matched cohort study in transgender individuals (the GAME study).
Jones P, Voisin S, Nolan B, Landen S, Jacques M, Newell B
BMJ Open. 2022; 12(5):e060869.
PMID: 35545400
PMC: 9096568.
DOI: 10.1136/bmjopen-2022-060869.
Effect of Wendler glottoplasty on voice and quality of life of transgender women.
Aires M, de Vasconcelos D, Lucena J, Gomes A, de Moraes B
Braz J Otorhinolaryngol. 2021; 89(1):22-29.
PMID: 34400103
PMC: 9874341.
DOI: 10.1016/j.bjorl.2021.06.010.
State-Level Policy Stigma and Non-Prescribed Hormones Use among Trans Populations in the United States: A Mediational Analysis of Insurance and Anticipated Stigma.
Hughes L, Gamarel K, King W, Goldenberg T, Jaccard J, Geronimus A
Ann Behav Med. 2021; 56(6):592-604.
PMID: 34390573
PMC: 9242548.
DOI: 10.1093/abm/kaab063.
Association of Documentation of Legal Residency Status with Nonprescribed Hormone Use Among Hispanic/Latina Trans Women in San Francisco.
Hernandez C, Santos G, Wilson E
Health Equity. 2021; 4(1):263-271.
PMID: 34095696
PMC: 8175253.
DOI: 10.1089/heq.2019.0104.
Research gaps in medical treatment of transgender/nonbinary people.
Safer J
J Clin Invest. 2021; 131(4).
PMID: 33586675
PMC: 7880308.
DOI: 10.1172/JCI142029.
Hormonal Gender Reassignment Treatment for Gender Dysphoria.
Meyer G, Boczek U, Bojunga J
Dtsch Arztebl Int. 2021; 117(43):725-732.
PMID: 33559593
PMC: 7871443.
DOI: 10.3238/arztebl.2020.0725.